Doppler quantitative evaluation and follow-up over 12 months in RA patients with moderate and high disease activity who are candidates for biologic add-on therapy with Adalimumab

The Karolinska Institute, ClinTRID0 个研究点目标入组 120 人开始时间: 2012年8月14日最近更新: 2024年8月26日

适应症

试验速览

暂无简介。

•Adult patient (> 18 years of age), male or female
•Rheumatoid arthritis according to the 1987 ACR or 2010 EULAR/ACR classification criteria
•Moderate to high disease activity
•Ongoing anti-rheumatic treatment with DMARD, with stable dosage during the last 3 months, and being a candidate for anti-TNF add-on therapy OR ongoing treatment with first anti-TNF therapy and being a candidate for switch to another anti-TNF therapy
•Women with child-bearing potential: use of an adequate method of contraception to avoid pregnancy throughout the study
•Signed Informed Consent*
•* Signed Informed Consent must be obtained before any study specific procedures take place.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Biologic treatment with Adalimumab before inclusion
•Two or more ongoing biologic treatments before inclusion
•Treatment with other biologic treatment than anti-TNF therapy before inclusion
•Any contraindication for treatment with Adalimumab
•Intraarticular corticosteroid injection during the last 4 weeks before each follow-up visit
•Positive for tuberculosis or hepatitis B.
•Ongoing pregnancy or lactation

发起方

The Karolinska Institute, ClinTRID